80
Active Trials
33
Phase 1
23
Phase 2
35
Phase 3
12
Therapeutic Areas
Portfolio Concentration: 60% of active trials in Oncology
Oncology
48 active / 54 total
Solid Tumor (Advanced)
14 active
14 total since 2015
NSCLC
5 active
3 Ph3
6 total since 2015
Multiple Myeloma
5 active
2 Ph3
5 total since 2015
Colorectal Cancer
4 active
2 Ph3
4 total since 2015
Pancreatic Cancer
3 active
1 Ph3
4 total since 2015
Prostate Cancer
3 active
1 Ph3
3 total since 2015
Breast Cancer
2 active
1 Ph3
4 total since 2015
Lung Cancer (General)
2 active
2 Ph3
3 total since 2015
Gastric Cancer
2 active
2 total since 2015
Head and Neck Cancer
1 active
1 total since 2015
HER2- Breast Cancer
1 active
1 total since 2015
Hematologic Malignancies
1 active
1 total since 2015
Triple Negative Breast Cancer
1 active
1 Ph3
1 total since 2015
Cholangiocarcinoma
1 active
1 total since 2015
SCLC
1 active
1 Ph3
1 total since 2015
Esophageal Cancer
1 active
1 total since 2015
Hepatocellular Carcinoma
1 active
1 Ph3
1 total since 2015
Cervical Cancer
0 active
1 total since 2015
Immunology
12 active / 15 total
Cardiovascular
6 active / 7 total
Metabolic
5 active / 5 total
CNS
4 active / 4 total
Respiratory
3 active / 3 total
Urology
2 active / 2 total
Musculoskeletal
2 active / 2 total
Rare Disease
1 active / 4 total
Women's Health
1 active / 2 total
Ophthalmology
0 active / 3 total
Gastrointestinal
0 active / 1 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)